<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499873</url>
  </required_header>
  <id_info>
    <org_study_id>TCTM/NEPA/2017</org_study_id>
    <nct_id>NCT03499873</nct_id>
  </id_info>
  <brief_title>Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension</brief_title>
  <official_title>A Randomized, Multicenter, Double Masked, Placebo Controlled, Parallel Group, Bioequivalence Study to Evaluate the Clinical Equivalence and Safety of Nepafenac 0.3% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Actavis LLC) With IlevroTM (Nepafenac Ophthalmic Suspension), 0.3% of Alcon Laboratories, Inc. for the Treatment of Pain and Inflammation Associated With Cataract Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence&#xD;
      study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension&#xD;
      (manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic&#xD;
      suspension), 0.3% of Alcon Laboratories, Inc. for the treatment of pain and inflammation&#xD;
      associated with cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Actual">December 18, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure at Day 14</measure>
    <time_frame>14 days</time_frame>
    <description>Number of participants that achieved cure at Day 14 defined as a score of 0 for aqueous cells (Grade 0-4 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance), a score of 0 for aqueous flare (Grade 0-3 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance) and a score of no more than 3 for pain (Grade 0-5 a positive sensation of the eye, including foreign body sensation, stabbing, throbbing or aching). The scoring indicates from less severe at 0 to very severe as the grading increases.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Nepafenac 0.3% Opthalmic Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ilevro 0.3% Opthalmic Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference product manufactured by Alcon Laboratories Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (vehicle) Opthalmic Suspension</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac 0.3% Oph Susp</intervention_name>
    <description>Nepafenac 0.3% Ophthalmic suspension (experimental product)</description>
    <arm_group_label>Nepafenac 0.3% Opthalmic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (vehicle) Opthalmic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac 0.3% Oph Susp (reference)</intervention_name>
    <description>Nepafenac 0.3% Ophthalmic suspension (Innovator)</description>
    <arm_group_label>Ilevro 0.3% Opthalmic Suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or non-pregnant, non-lactating females, 18 years of age or older who have a&#xD;
             cataract and are expected to undergo cataract extraction.&#xD;
&#xD;
          2. No aqueous cells, no visible aqueous flare and no significant ocular pain in the&#xD;
             selected eye noted during the Screening visit by slit-lamp examination.&#xD;
&#xD;
          3. Study subjects must have provided IRB approved written informed consent using the&#xD;
             latest version of the IRB informed consent form. In addition, study subjects must sign&#xD;
             a HIPAA authorization, if applicable.&#xD;
&#xD;
          4. Study subjects should be literate and willing to complete the subject diary regularly&#xD;
             as directed.&#xD;
&#xD;
          5. Study subjects must be in good health and free from any clinically significant disease&#xD;
             apart from indication under study.&#xD;
&#xD;
          6. Females of child bearing potential (WOCBP*) must not be pregnant or lactating at&#xD;
             baseline visit (as documented by a negative urine pregnancy test with a minimum&#xD;
             sensitivity of 25 IU/L or equivalent units of beta-human chorionic gonadotropin&#xD;
             (Beta-HCG) at screening and urine pregnancy at baseline.&#xD;
&#xD;
          7. Female subjects of childbearing potential must be willing to use an acceptable form of&#xD;
             birth control from the day of the first dose administration to 30 days after the last&#xD;
             administration of IP. For the purpose of this study the following are considered&#xD;
             acceptable methods of birth control: oral or injectable contraceptives, contraceptive&#xD;
             patches, Depo-ProveraÂ® (Medroxyprogesterone acetate-stabilized for at least 3 months);&#xD;
             vaginal contraceptive; contraceptive implant; double barrier methods (e.g. condom and&#xD;
             spermicide); Nuvaring vaginal hormonal birth control, IUD, or abstinence with a second&#xD;
             method of birth control should the subject become sexually active. A sterile sexual&#xD;
             partner is NOT considered an adequate form of birth control.&#xD;
&#xD;
          8. All male subjects must agree to use accepted methods of birth control with their&#xD;
             partners, from the day of the first dose administration (to 30 days after the last&#xD;
             administration of study drug). Please see acceptable forms for &quot;Female&quot; birth control&#xD;
             above. Abstinence is an acceptable method of birth control for males.&#xD;
&#xD;
          9. Study subjects must be willing and able to understand and comply with the requirements&#xD;
             of the protocol, including attendance at the required scheduled study visits.&#xD;
&#xD;
         10. Study subjects must be willing to refrain from using any other treatments other than&#xD;
             the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, breast feeding, or planning a pregnancy during the course of&#xD;
             the study and for 30 days after last study dose.&#xD;
&#xD;
          2. Females of childbearing potential who do not agree to utilize an adequate form of&#xD;
             contraception.&#xD;
&#xD;
          3. Current or past history of severe hepatic or renal impairment, uncontrolled diabetes&#xD;
             mellitus, rheumatoid arthritis or bleeding tendencies.&#xD;
&#xD;
          4. Current or history within two months prior to baseline of clinically significant&#xD;
             ocular disease, e.g., corneal denervation, corneal epithelial defects, severe dry eye&#xD;
             syndrome, ocular trauma to the operative eye, corneal edema, proliferative diabetic&#xD;
             retinopathy in the operative eye or ocular infection.&#xD;
&#xD;
          5. In the operative eye, history of chronic or recurrent inflammatory disease, e.g.,&#xD;
             iritis, scleritis, uveitis, iridocyclitis or rubeosis iritis, lens pseudoexfoliation&#xD;
             syndrome with glaucoma or zonular compromise.&#xD;
&#xD;
          6. Congenital ocular anomaly, e.g., aniridia or congenital cataract.&#xD;
&#xD;
          7. Iris atrophy in the operative eye.&#xD;
&#xD;
          8. Current corneal abnormalities that would prevent accurate IOP readings with the&#xD;
             Goldmann applanation tonometer.&#xD;
&#xD;
          9. Nonfunctional nonoperative eye (visual acuity of 20/200 or worse Snellen or ETDRS).&#xD;
&#xD;
         10. Known hypersensitivity to any component of nepafenac therapy or to other nonsteroidal&#xD;
             anti-inflammatory drug (NSAID).&#xD;
&#xD;
         11. Use within one week prior to baseline of: 1) contact lens, or 2) topical, ophthalmic&#xD;
             or systemic NSAID.&#xD;
&#xD;
         12. Use within two weeks prior to baseline of: 1) topical ophthalmic corticosteroid, 2)&#xD;
             topical corticosteroid, or 3) medications which may prolong bleeding time (per&#xD;
             investigator discretion and primary care physician approval to discontinue use for&#xD;
             surgery).&#xD;
&#xD;
         13. Use within one month prior to baseline of: 1) systemic corticosteroid, 2) high-dose&#xD;
             salicylate therapy, or 3) topical ophthalmic prostaglandin analogs, e.g., bimatoprost,&#xD;
             latanoprost or travoprost.&#xD;
&#xD;
         14. Use within six months prior to baseline of intravitreal or subtenon injection of&#xD;
             ophthalmic corticosteroid.&#xD;
&#xD;
         15. Underwent within six months prior to baseline any complicated intraocular surgery or&#xD;
             repeat ocular surgeries (e.g., cataract surgery).&#xD;
&#xD;
         16. Underwent within twelve months prior to baseline: refractive surgery, filtering&#xD;
             surgery or laser surgery for IOP reduction.&#xD;
&#xD;
         17. History or presence of significant alcoholism or drug abuse in the past one year.&#xD;
&#xD;
         18. History or presence of significant smoking (more than 20 cigarettes or any other&#xD;
             equivalent tobacco product/day).&#xD;
&#xD;
         19. History of hematologic disorders other than mild anemia.&#xD;
&#xD;
         20. Severe, unstable, or uncontrolled cardiovascular or pulmonary disease.&#xD;
&#xD;
         21. Therapy with an investigational agent within the past 30 days prior to screening.&#xD;
&#xD;
         22. Clinically significant hematologic and / or biochemical abnormalities based on&#xD;
             laboratory testing.&#xD;
&#xD;
         23. Subjects who are in the investigator's best judgment at risk of visual field or visual&#xD;
             acuity worsening as a consequence of participation in trial.&#xD;
&#xD;
         24. Use of any prescribed medication during last two weeks or OTC medicinal products&#xD;
             during the last one week preceding the first dosing that results in drug-drug&#xD;
             interaction with the study drug.&#xD;
&#xD;
         25. Major illness, as per investigator discretion, during 3 months before screening.&#xD;
&#xD;
         26. Subjects who are employees of site or CRO or sponsor or immediate family of employees.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Key-Whitman Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <results_first_submitted>January 11, 2021</results_first_submitted>
  <results_first_submitted_qc>January 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2021</results_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03499873/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT03499873/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nepafenac 0.3% Opthalmic Suspension</title>
          <description>Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Nepafenac 0.3% Oph Susp: Nepafenac 0.3% Ophthalmic suspension (experimental product)</description>
        </group>
        <group group_id="P2">
          <title>Ilevro 0.3% Opthalmic Suspension</title>
          <description>Reference product manufactured by Alcon Laboratories Inc.&#xD;
Nepafenac 0.3% Oph Susp (reference): Nepafenac 0.3% Ophthalmic suspension (Innovator)</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Vehicle) Opthalmic Suspension</title>
          <description>Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Placebos: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="182"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-Protocol Population</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="143"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified-Intent-to-Treat</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subjects condition worsened</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Concomitant therapy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigational Product (IP) Missed dose compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics provided for Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Nepafenac 0.3% Opthalmic Suspension</title>
          <description>Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Nepafenac 0.3% Oph Susp: Nepafenac 0.3% Ophthalmic suspension (experimental product)</description>
        </group>
        <group group_id="B2">
          <title>Ilevro 0.3% Opthalmic Suspension</title>
          <description>Reference product manufactured by Alcon Laboratories Inc.&#xD;
Nepafenac 0.3% Oph Susp (reference): Nepafenac 0.3% Ophthalmic suspension (Innovator)</description>
        </group>
        <group group_id="B3">
          <title>Placebo (Vehicle) Opthalmic Suspension</title>
          <description>Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Placebos: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="174"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="429"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.1" spread="8.73"/>
                    <measurement group_id="B2" value="68.5" spread="9.12"/>
                    <measurement group_id="B3" value="67.0" spread="10.19"/>
                    <measurement group_id="B4" value="68.1" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Iris Colour</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Blue</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Green</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grey</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hazel</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Brown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Ocular Pain Grade in Study Eye</title>
          <description>Grade 0-5 a positive sensation of the eye, including foreign body sensation, stabbing, throbbing or aching. The scoring indicates from less severe at 0 to very severe as the grading increases.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0 (less severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 5 (most severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Aqueous Cells Grade in Study Eye</title>
          <description>Grade 0-4 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0 (least severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 4 (most severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Aqueous Flare Grade in Study Eye</title>
          <description>Grade 0-3 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Grade 0 (least severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="426"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade 3 (most severe)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cure at Day 14</title>
        <description>Number of participants that achieved cure at Day 14 defined as a score of 0 for aqueous cells (Grade 0-4 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance), a score of 0 for aqueous flare (Grade 0-3 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance) and a score of no more than 3 for pain (Grade 0-5 a positive sensation of the eye, including foreign body sensation, stabbing, throbbing or aching). The scoring indicates from less severe at 0 to very severe as the grading increases.</description>
        <time_frame>14 days</time_frame>
        <population>Per-Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>Nepafenac 0.3% Opthalmic Suspension</title>
            <description>Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Nepafenac 0.3% Oph Susp: Nepafenac 0.3% Ophthalmic suspension (experimental product)</description>
          </group>
          <group group_id="O2">
            <title>Ilevro 0.3% Opthalmic Suspension</title>
            <description>Reference product manufactured by Alcon Laboratories Inc.&#xD;
Nepafenac 0.3% Oph Susp (reference): Nepafenac 0.3% Ophthalmic suspension (Innovator)</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Vehicle) Opthalmic Suspension</title>
            <description>Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Placebos: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Cure at Day 14</title>
          <description>Number of participants that achieved cure at Day 14 defined as a score of 0 for aqueous cells (Grade 0-4 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance), a score of 0 for aqueous flare (Grade 0-3 using a narrow-slit beam (0.5 mm width at least 8 mm length) at maximum luminance) and a score of no more than 3 for pain (Grade 0-5 a positive sensation of the eye, including foreign body sensation, stabbing, throbbing or aching). The scoring indicates from less severe at 0 to very severe as the grading increases.</description>
          <population>Per-Protocol Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% CI on the Test-to-Reference difference for the proportion of subjects with cure should be contained within the interval [-0.20, +0.20]</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.026</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.124</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nepafenac 0.3% Opthalmic Suspension</title>
          <description>Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Nepafenac 0.3% Oph Susp: Nepafenac 0.3% Ophthalmic suspension (experimental product)</description>
        </group>
        <group group_id="E2">
          <title>Ilevro 0.3% Opthalmic Suspension</title>
          <description>Reference product manufactured by Alcon Laboratories Inc.&#xD;
Nepafenac 0.3% Oph Susp (reference): Nepafenac 0.3% Ophthalmic suspension (Innovator)</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Vehicle) Opthalmic Suspension</title>
          <description>Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.&#xD;
Placebos: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Altered visual depth perception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anterior chamber cell</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anterior chamber disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anterior chamber fibrin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Anterior chamber inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Conjunctival cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Corneal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Corneal oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Eyelid exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypotony of eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Keratic precipitates</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ocular hypertention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Posterior capsule rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vitreous degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fibrin deposition on lens postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Iris injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="174"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study may be published or presented by the Investigator(s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, CE Studies</name_or_title>
      <organization>Teva Pharmaceuticals USA, Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

